Burr Ridge, IL

Metro Infectious Disease Consultants

COVID-19

Recurrence

Infections

Communicable Diseases

Dysentery

Diarrhea

Clostridium Infections

Remdesivir

Obeldesivir

Gilead Sciences

Finch Therapeutics

Vedanta Biosciences

condition

allSponsorName

gender

Male

Female

overallStatus

Recruiting

Not yet recruiting

Active, not recruiting

Enrolling by invitation

Completed

Terminated

Withdrawn

Suspended

Unknown

type

Interventional

Observational

Expanded Access

phase

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Not Applicable

funderTypes

Industry

Other U.S. Federal agency

All others

ageGroup

Child (birth-17)

Adult (18-64)

Older Adult (65+)

The overall objective of the RESTORATiVE303 study is to evaluate the safety and the Clostridioides difficile infection (CDI) recurrence rate at Week 8 in participants who receive a 14-day course of VE303 or matching placebo. The objectives and endpoints are identical for Stage 1 (recurrent CDI) and Stage 2 (high-risk primary CDI).

VE303 for Prevention of Recurrent Clostridioides Difficile Infection

Metro Infectious Disease Consultants | Burr Ridge, IL

Site insights

Work at this site?

Active trials

VE303 for Prevention of Recurrent Clostridioides Difficile Infection (RESTORATiVE303)

Trial sponsors